Please login to the form below

Not currently logged in
Email:
Password:

Data supports Actemra's effectiveness

New two-year data has shown the effectiveness of Actemra in inhibiting structural damage to the joints of patients with rheumatoid arthritis, Roche has announced

New two-year data has shown the effectiveness of Actemra (tocilizumab) in inhibiting structural damage to the joints of patients with rheumatoid arthritis (RA), Roche has announced.

The Swiss drug maker said the data also improved patients' ability to perform everyday activities and helped maintain high remission rates.

Included in the data, x-rays of bone erosions and a narrowing of joint spaces showed that more patients treated with Actemra in combination with the current therapy, methotrexate, saw a significant inhibition in structural damage during 24 months of treatment when compared to patients in a control group.

The randomised LITHE study involved 1,196 patients with moderate to severe RA who previously had an inadequate response to methotrexate. Patients were administered either Actemra once every four weeks in a combination with methotrexate, or methotrexate alone.

Full data from the trial will be used to support regulatory filings for labelling claims. Actemra is currently already approved in Japan and Europe for the above usage.

26th May 2009

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
claire@dovetailstrategies.com

About Dovetail We’re award-winning specialists in healthcare collaboration that makes patients’ lives better. Combining expertise with a passion for collaboration,...

Latest intelligence

Virtual Hackathon on Healthcare Innovation: a Customer Story
How participants from 9 different countries in the APAC region were brought together to participate in a pharmaceutical company-wide 3-day virtual "hackathon," with spectacular results....
OPEN Health at the World Orphan Drug Conference USA
Our Director of Rare Disease, Gavin Jones looks forward to his conversation with Emily Crossle & Betsy Bogard at #WODCUSA2020 !...
Can involving patients in design transform the clinical trial experience?
While the research space is a heavily regulated environment and there are rules that we must abide by, this doesn’t mean clinical study materials have to be ‘boring’ or the...

Infographics